2/ Abstract Number: 606 - B0243. Echeverri Tribin F et al. Inhibition of Multidrug-Resistant Pseudomonas aeruginosa with Rose Bengal Photodynamic Antimicrobial Therapy: In vitro. Conclusions: MDR Pseudomonas aeruginosa can be inhibited by rose bengal eppro02.ativ.me/web/page.php?p…… twitter.com/i/web/status/1…
3/ Abstract Number: 609 - B0246. Krishna et al. In vitro Inhibition of Aspergillus and Fusarium Species with Erythrosin B, Eosin Y, and Rose Bengal Photodynamic Antimicrobial Therapy. Conclusions: EB, EY, and RB with light were effective against both F. eppro02.ativ.me/web/page.php?p…… twitter.com/i/web/status/1…
4/ Abstract Number: 3294. Rocchetti et al. Action of Rose Bengal photoactivated by green light associated or not to Propamidine Isethionate and/or Polyhexamethyl Biguanide on Acanthamoeba trophozoites cells – in vitro study. Conclusions: This in vitro eppro02.ativ.me/web/page.php?p…… twitter.com/i/web/status/1…
5/ Abstract Number: 4027 - B0344. Chen et al. Rose Bengal Penetration Depth with Iontophoresis in Human Cornea Tissue. Conclusions: Corneal penetration of RB disodium is significantly improved by utilizing iontophoresis. These findings support the eppro02.ativ.me/web/page.php?p…… twitter.com/i/web/status/1…
2/ “Everyone” seems to know or understand #RoseBengal, but do they (you) really?
3/ #RoseBengal is a small molecule (i.e., <1,000 Daltons*), but a “heavy” one at 973.67 Da or g/mol. It is heavy because of its four iodides, which comprise 52% of its molecular weight.
1/ “Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.” $PVCT thoughts: there’s no free lunch. A THREAD.
2/ 20Mar23: Endpoints: “BioNTech to pay $200M upfront in CTLA-4 antibody development, commercialization deal.” endpts.com/biontech-to-pa….
$PVCT-related medical journal article: DePalo DK, Zager JS. Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. Cancers. 2023; 15(5):1404. doi.org/10.3390/cancer…. @MoffittNews@USFHealthMed. Intralesional agent PV-10… twitter.com/i/web/status/1…
Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-naïve Stage III cutaneous melanoma
Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-refractory advanced melanoma
2/ Over the past decade-plus, cancer immunotherapy with antibodies targeting the PD-1 immune checkpoint pathway (i.e., PD-1 inhibitors #PD1) has yielded dramatic improvement in clinical outcome for many patients with #CutaneousMelanoma. #Keytruda#Opdivo#otherPD1s#PDL1s
3/ However, patients with Stage III disease and, in particular, those with in-transit disease (i.e., in-transit melanoma; ITM #IntransitMelanoma), have presented unique challenges with regard to response rate and durability of response.
2/ This $PVCT #thread will be an ongoing one for some time. Please check back to read it again (and again), and learn more about our medical scientific history and our lead molecule #RoseBengalSodium’s journey to becoming a multi-disease, broad-spectrum, therapeutic compound.
3/ #Covid has been a deeply painful experience, to say the least, for the U.S. and the world. It also marked a turning point in the advancement and expansion of our #HX medical science platform, as well as our lead molecule #RoseBengalSodium and the investigational drugs and drug… twitter.com/i/web/status/1…
3/ In 2023, $PVCT expects research collaborators at different academic medical institutions to read out data from their preclinical research work under newly established and existing #SRAs. #research. #rosebengal#rosebengalsodium.